Teva Pharmaceutical Industries (NYSE: TEVA ) is expected to report Q4 earnings on Feb. 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries's revenues will wither -7.5% and EPS will contract -16.4%.
The average estimate for revenue is $5.25 billion. On the bottom line, the average EPS estimate is $1.33.
Last quarter, Teva Pharmaceutical Industries reported revenue of $4.97 billion. GAAP reported sales were 14% higher than the prior-year quarter's $4.34 billion.
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS were -$0.09 for Q3 against $1.03 per share for the prior-year quarter.
For the preceding quarter, gross margin was 52.3%, 20 basis points better than the prior-year quarter. Operating margin was 21.5%, 390 basis points worse than the prior-year quarter. Net margin was -1.6%, 2,270 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $20.34 billion. The average EPS estimate is $5.36.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,470 members out of 2,540 rating the stock outperform, and 70 members rating it underperform. Among 584 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 576 give Teva Pharmaceutical Industries a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $50.28.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Teva Pharmaceutical Industries to My Watchlist.